A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

A Phase I Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

The purpose of this study is to assess priming with antigenically mismatched live attenuated A/H7N3 influenza virus vaccine followed by inactivated A/H7N9 influenza virus vaccine in healthy adults.

Study Overview

Status

Completed

Conditions

Detailed Description

This study will assess priming with antigenically mismatched live attenuated A/H7N3 influenza virus vaccine (H7N3 pLAIV) followed by inactivated A/H7N9 influenza virus vaccine (H7N9 pIIV) in healthy adults.

Participants will receive a dose of H7N3 pLAIV on Days 0 and 28, followed by a single dose of H7N9 pIIV on Day 84.

On Days -2 and 26, participants will be admitted to an inpatient clinic. They will receive the H7N3 pLAIV vaccine on Days 0 and 28. They will remain in the clinic for 9 days after receiving the vaccine and until they are no longer shedding vaccine virus. An additional study visit will occur on Day 56.

On Day 84, participants will receive the H7N9 pIIV vaccine. Additional study visits will occur on Days 87, 91, 98, 112, 140, and 180. Study visits may include physical examinations, nasal washes, and blood and urine collection. Participants will be contacted by phone on Day 264 for follow-up health monitoring.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center Vaccine Research Unit (Outpatient)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult males and non-pregnant, non-breastfeeding females between 18 years and 49 years of age, inclusive. Children will not be recruited or enrolled in this study because they are not in the apparent risk group, for safety considerations, and because of the need for isolation.
  • Are in good health, as determined by medical history and targeted physical examination to ensure any existing medical diagnoses or conditions (except those exclusionary) are stable. More information on this criterion can be found in the protocol.
  • Agree to storage of blood specimens for future research.
  • Available for the duration of the trial. Subjects must be willing and able to remain within the Isolation Unit for the specified duration of confinement.
  • Provide written informed consent prior to initiation of any study procedures, including future use of specimens.
  • Female subjects of child-bearing potential must agree to use effective birth control methods for the duration of the study (for example, pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; intrauterine device; abstinence from heterosexual intercourse, surgical sterilization). All female subjects will be considered being of child bearing potential except those who have undergone hysterectomy or tubal ligation and those in whom menopause occurred at least 1 year prior to the study.
  • Agrees not to participate in another clinical trial with an investigational product for the entire duration of the study.
  • Female subjects of childbearing potential must have a negative urine and serum pregnancy test within 24 hours (urine) to 48 hours (serum) prior to study vaccination.

Exclusion Criteria:

  • Pregnancy as determined by a positive human choriogonadotropin (beta-HCG) test.
  • Currently breastfeeding or planning to breastfeed or become pregnant at some point during the duration of the study.
  • Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, electrocardiogram (EKG) and/or laboratory studies including urine testing. Alanine aminotransferase (ALT) levels greater than 2 times the upper normal limit will be exclusionary at baseline, prior to vaccination.
  • Any current illness requiring daily medication other than the following: vitamins, birth control, anti-hypertensive medication, antihistamines, anti-depressant medication, cholesterol-lowering medication, treatment for gastroesophageal reflux disease, and thyroid medication unless approved by the principal investigator (PI).
  • Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol.
  • Previous enrollment in an H7 vaccine trial or in any study of an avian influenza vaccine.
  • Seropositive to the H7N3 or H7N9 influenza A virus (serum HAI titer greater than 1:8).
  • Positive urine drug toxicology test indicating narcotic use/dependency.
  • Have medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
  • Other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.
  • Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines.
  • Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccine.
  • Allergy to oseltamivir as determined by subject report.
  • Current diagnosis of asthma or reactive airway disease (within the past 2 years).
  • History of Guillain-Barré Syndrome.
  • Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory Western blot tests for human immunodeficiency virus-1 (HIV-1).
  • Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for hepatitis C virus (HCV).
  • Positive hepatitis B virus surface antigen (HBsAg) by ELISA.
  • Known immunodeficiency syndrome.
  • Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination.
  • Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination.
  • History of asplenia
  • Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior to vaccination.
  • Have known active neoplastic disease or a history of any hematologic malignancy.
  • Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination.
  • Current smoker unwilling to stop smoking for the duration of the inpatient stay.

    • A current smoker includes anyone stating they currently smoke or use any amount of a tobacco product, including electronic cigarettes.
    • After admission to the unit, nicotine patches will be provided to current smokers who request them for the inpatient portion of the study.
  • Travel to the Southern Hemisphere within 14 days prior to study vaccination.
  • Travel on a cruise ship within 14 days prior to study vaccination.
  • Receipt of another investigational vaccine or drug within 30 days prior to study vaccination.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: H7N3 pLAIV + H7N9 pIIV
Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
Approximately 10^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
Other Names:
  • Live attenuated A/H7N3 influenza virus vaccine
30 micrograms administered by intramuscular (IM) injection
Other Names:
  • Inactivated A/H7N9 influenza virus vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemagglutination-inhibition (HAI) antibody response to H7N9 virus following administration of pIIV
Time Frame: Measured through Day 28
Defined as 4-fold or greater response to a titer of 1:40 or above with 95% confidence intervals for both antigens
Measured through Day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of reactogenicity events following each dose of vaccine
Time Frame: Measured through Day 180
Reactogenicity events will be collected and assessed for each individual subject, taking the pattern of viral shedding into account.
Measured through Day 180
Severity of reactogenicity events following each dose of vaccine
Time Frame: Measured through Day 180
Assessed according to the Reactogenicity Event Severity Grading System provided in the protocol
Measured through Day 180
Frequency of adverse events following each dose of vaccine
Time Frame: Measured through Day 180
All adverse events will be recorded and relationship to study product will be assessed.
Measured through Day 180
Severity of adverse events following each dose of vaccine
Time Frame: Measured through Day 180
Assessed according to the Adverse Event Severity Grading System provided in the study protocol
Measured through Day 180
Frequency of vaccine viral shedding after each dose
Time Frame: Measured through Day 180
Determined by rtRT-PCR and culture at each day tested after inoculation
Measured through Day 180
Serum HAI and neutralizing antibody response following 1 or 2 doses of pLAIV
Time Frame: Measured through Day 56
Response rates defined as 4-fold or greater response to a titer of 1:40 or above with 95% confidence intervals for both antigens
Measured through Day 56
Neutralizing and HAI responses after pIIV boost against antigenic variants of H7 virus, including H7N7, H7N3, and H7N9 North American and Eurasian lineage viruses
Time Frame: Measured through Day 28
Response rates defined as 4-fold or greater response to a titer of 1:40 or above with 95% confidence intervals for both antigens
Measured through Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Angela Branche, M.D., University of Rochester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 19, 2017

Primary Completion (ACTUAL)

September 14, 2018

Study Completion (ACTUAL)

February 6, 2019

Study Registration Dates

First Submitted

June 26, 2018

First Submitted That Met QC Criteria

June 26, 2018

First Posted (ACTUAL)

July 10, 2018

Study Record Updates

Last Update Posted (ACTUAL)

March 25, 2019

Last Update Submitted That Met QC Criteria

March 22, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Influenza

Clinical Trials on H7N3 pLAIV

3
Subscribe